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Abstract
Background:  There is still much debate about the best adjuvant therapy after surgery for
endometrial cancer (EC) and there are no current guidelines. Radiotherapy (RT) alone does not
seem to improve overall survival. We investigated whether concomitant Paclitaxel (P) and RT gave
better clinical results.
Methods:  Twenty-three patients with high-risk EC (stage IIB, IIIA, IIIC or IC G3 without
lymphadenectomy or with aneuploid tumor) underwent primary surgery and were then referred
for adjuvant therapy. P was given at a dose of 60 mg/m2 once weekly for five weeks during RT,
which consisted of a total radiation dose of 50.4 Gy. Three further weekly cycles of P at a dose of
80 mg/m2 were given at the end of RT. Overall survival and disease-free survival were calculated
from the time of surgery. Patterns of failure were recorded by the sites of failure.
Results: A total of 157 cycles of P were administered both during radiotherapy and consolidation
chemotherapy.
Relapses occurred in five patients (21.7%). Median time to recurrence was 18.6 months (range 3–
28). Survival rate for all the patients was 78.2%. Overall survival for the patients who completed
chemo-radiation was of 81%. In this group median time to recurrence was 19.2 months (range 3–
28). All recurrences were outside the radiation field. Mortality rate was 14.2%.
Conclusion: This small series demonstrates pelvic radiotherapy in combination with weakly P
followed by three consolidation chemotherapy cycles as an effective combined approach in high
risk endometrial carcinoma patients.
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Background
Patients with endometrial cancer (EC) are traditionally
divided into risk categories, conventionally based on ana-
tomical-surgical prognostic factors. The most significant
prognostic factors are stage, histologic type, depth of myo-
metrial invasion, grade of differentiation and lymph-node
metastases [1]. Stage IC poorly differentiated, and stages II
and III-IV show five-year survival rates ranging from
approximately 20 to 60%, thus all requiring additional
treatment [2]. Traditional prognostic factors, however,
cannot define the prognosis for all patients. DNA content
analysis can be useful to assess the risk of recurrence more
precisely and ploidy appears to be one of the most impor-
tant prognostic factors in EC [3-5].
There is much debate about the best adjuvant therapy
after surgery and there are no accepted guidelines for this
treatment. EC patients often receive adjuvant radiation
therapy to reduce the risk of pelvic relapse [6,7] but this
does not seem to improve overall survival because it can-
not reduce the risk of distant recurrences. On the other
hand, the efficacy of adjuvant chemotherapy alone has
not been proved yet [8,9]. A new combined adjuvant
treatment is therefore needed to improve results in high-
risk EC patients.
Paclitaxel (P) has shown in vitro and clinical activity
against EC and is also a potent radiosensitizer [10]. The
goal of this trial was to try out a new regimen of combined
chemotherapy and radiation therapy. The toxicity and
safety of concomitant P and radiotherapy (RT) have
already been evaluated [11] We report the results in 23
high-risk EC patients, meaning advanced stages, IC G3
and aneuploid tumors, treated with P and RT.
Methods
Twenty-three patients with high-risk EC underwent pri-
mary surgery in our Institution or were referred just for
adjuvant therapy. All were surgically treated with abdom-
inal hysterectomy, bilateral salpingo-oophorectomy and
peritoneal cytology; pelvic lymphadenectomy was done
in 13 patients. In the other cases lymph node status was
unknown because these patients were either referred to
our Institution after primary surgery or randomized
between pelvic lymphadenectomy and nodes sampling
only if grossly involved. No systematic periaortic dissec-
tion was performed in these cases. Patients with macro-
scopic periaortic positive nodes were excluded.
Stages included IIB, IIIA (patients with positive washings
without other unfavorable prognostic factors were omit-
ted), IIIB and IIIC or IC G3 without lymphadenectomy or
with aneuploid tumor (DNA index >1.2). Histologic types
other than endometrioid adenocarcinoma were excluded.
All the histological samples were examined by the same
pathologist and in all the cases DNA ploidy was deter-
mined from paraffin-embedded tissue.
All the following criteria were satisfied: WHO perform-
ance status 0–1; adequate bone marrow reserve (neu-
trophil count >1.5, platelet count >100000 and Hb >10 g/
dL), adequate liver function (serum bilirubin <1.5, serum
transaminases < twice the upper limit of normal), ade-
quate renal function (serum creatinine <1.5 mg/dL), no
chronic cardiac or bowel diseases, age >18 years and <75
years. Patients with an history of other invasive cancer
(except basal cell carcinoma of the skin) and previous
chemotherapy or radiotherapy were excluded. The inter-
val between surgery and RT had to be less than six weeks.
Ethical approval was obtained from Ethical Committee of
the Scientific Institution of San Raffaele Hospital of
Milan.
Written informed consent was obtained from all patients
before they entered the study.
P at a dose of 60 mg/m2 was infused intravenously in 250
mL of normal saline for 1 hour once weekly during RT for
five weeks. Standard anaphylaxis premedication was
given. The radiation plan consisted of a total dose of 50.4
[34] Gy, given in five fractions per week (1.8 Gy: daily
dose) for six weeks. The irradiation field encompassed the
entire pelvis as follows: the high limit was tangential to
the upper surface of L5, the lower limit comprised the
upper third of the vagina, and the lateral limits were not
less than 2 cm outside the ileopectineal ligament.
Two IIIC patients underwent extended field irradiation.
Brachytherapy was used in IIIB patient. Three further
cycles of P, at a dose of 80 mg/m2, were given weekly at
the end of RT.
Both chemotherapy and radiation therapy were delayed if,
at the time of recovery, the neutrophil count was less than
1.0 × 109/L or platelets were less than 100 × 109/L. For all
other toxicity we used the WHO toxicity scale. Chemo-
therapy was discontinued after two consecutive weeks of
delay; when this happened patients continued RT alone.
Patients were assessed every three months for the first
three years, every six months for the fourth and fifth year,
then yearly.
Overall and disease-free survival were evaluated from the
time of surgery. Survival rates was calculated according to
intent to treat. Secondary we studied survival rates in the
patients who completed at least five cycles of chemother-
apy and all the RT in assessing the efficacy of this treat-
ment.BMC Cancer 2006, 6:198 http://www.biomedcentral.com/1471-2407/6/198
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Patterns of failure were recorded by the sites of failure:
locoregional within the irradiated area, distant outside the
irradiated area, or both.
Results
The 23 patients with EC followed up for 16–48 months
(median 34 months). Table 1 shows the main characteris-
tics of the whole group. Five had metastatic lymph nodes.
Six were stage IC, 4 stage IIB, 7 IIIA, 1 IIIB and 5 IIIC.
Twenty-one patients had more than 50% myometrial
infiltration; two stage IIIA cases only had less than 50%
uterine infiltration. Two patients had well differentiated
tumors, 8 were moderate tumors and 13 were poorly dif-
ferentiated. DNA ploidy was determined in all patients on
paraffin-embedded tissues: seven had aneuploidy
(defined as a DNA index >1.2).
Two patients who stopped chemotherapy before the end
of RT did not complete at least five cycles of chemother-
apy. The first one had a tumor stage IIIA and presented an
anaphylactic reaction to P at the first cycle and continued
RT alone; she had a periaortic recurrence after six months
and died of disease after 20 months of follow-up. The
other, with a tumor stage IIB, refused to continue chemo-
therapy at the second cycle of P, without any toxicity, and
died ten months later from a pericardial mesothelioma.
One-hundred and fifty-seven P cycles were administered
both during radiotherapy and consolidation chemother-
apy. Adverse effects were individually evaluated and
recorded. There was no life-threatening toxicity. No
patients required hospitalization or ER visits for acute tox-
icity. Adverse effects are summarized in Table 2.
No dose reduction was required. Eight cycles were delayed
one week, in four cases for grade 3 neutropenia, in three
for severe diarrhea and one for increased liver enzymes.
No patients presented emesis.
Hematological toxicity was mild in other cases without
reduction of doses or delay of treatment. No blood trans-
fusions or hematologic support were administered in
these patients. One patient developed anaphylactic clini-
cal reaction and suspended the chemotherapy. No
patients developed alopecia.
Delayed toxicity included one case of incomplete small
intestinal obstruction 8 weeks after the end of the treat-
ment with medical resolution. Three patients reported
mild recurrent intestinal dysfunctions (stipsis and/or
diarrhea). One patient presented recurrent cystitis related
to the treatment.
Relapses occurred in five patients (21.7%). Median time
to recurrence was 18.6 months (range 3–28). None of the
five stage IIIC patients with metastatic pelvic nodes devel-
oped periaortic recurrences (Table 3).
Table 1: Patients' main characteristics
Age Grade Myometrial invasion Ploidy Stage Lymph node status
1 54 3 2 1.00 IIB Negative
2 50 2 2 1.00 IIIA Negative
36 7 3 2 1 . 0 0 I I B N o t  d o n e
46 7 3 2 1 . 0 0 I C N o t  d o n e
5 64 2 2 1.00 IIIC Positive
66 7 3 2 1 . 3 0 I I I A N o t  d o n e
7 63 2 2 1.50 IIIC Positive
8 48 3 2 1.30 IC Negative
96 2 2 1 1 . 0 0 I I I A N o t  d o n e
10 55 2 2 1.00 IIIC Positive
11 62 3 2 1.00 IC Not done
12 69 3 2 1.60 IC Not done
13 71 2 2 1.00 IIIA Negative
14 64 1 2 1. 00 IIIA Negative
15 71 2 2 1.90 IIIC Positive
16 63 3 2 1.80 IIIC Positive
17 71 3 2 1.00 IC Not done
18 74 3 2 1.50 IIIB Negative
19 65 2 2 1.00 IIIA Not done
20 61 3 2 1.00 IIB Negative
21 64 3 2 1.20 IIB Negative
22 51 1 1 1.00 IIIA Not done
23 61 3 2 1.00 IC Not doneBMC Cancer 2006, 6:198 http://www.biomedcentral.com/1471-2407/6/198
Page 4 of 7
(page number not for citation purposes)
Final event, defined according to date of death or last con-
tact, showed 17 patients (73.9%) still alive and free from
disease, one alive with tumor, four dead for disease.
Another patient died from another primary tumor.
Overall survival of the patients who completed chemo-
radiation was 81%. In this group median time to recur-
rence was 19.2 months. All recurrences were outside the
radiation field. One patient presented a periaortic and
pulmonary relapse 28 months after surgery and died 45
months from diagnosis; one had an abdominal relapse
after 25 months and died 48 months from surgery. The
third developed a periaortic nodule, outside the radiation
field, after three months and died after 18 months of fol-
low-up. The fourth patient had a skeletal relapse after 21
months but is alive after 26 months of follow-up. All these
patients completed 8 cycles of chemotherapy in combina-
tion with radiotherapy. The patients with cancer relapse
were treated in four cases with chemotherapy (Cisplatin
and Doxorubicine) and in one case with hormonal treat-
ment.
Discussion and conclusion
Although there have been improvements in RT and chem-
otherapy, during the last few years survival for high-risk
EC has not increased. Reported five-year survival rates are
70% for stage II, 50% for stage III, and 27% for stage IV
[12]. This has prompted the search for new therapeutic
strategies in recent decades. Looking at the literature it
seems that surgery alone could be the treatment of choice
for low-risk EC but more aggressive treatments are appro-
priate for high-risk EC.
The role of adjuvant RT in the treatment of EC has
remained controversial due to a lack of information from
randomized trials. Retrospective analysis suggested that
the risk of locoregional relapse was reduced but overall
survival rates did not seem to be improved. Three rand-
omized trials comparing no therapy vs RT showed a
reduction of pelvic relapses in the RT patients but not in
overall survival rates. did not change [13-15].
Whole abdominal radiation therapy has also been
employed in particular in the treatment of advanced
endometrial cancer; Sutton et al found 29% recurrence
free survival in patients with endometrial adenocarcino-
mas stage III-IV with gross residual disease, gross extrau-
terine spread with all disease resected or microscopic
extrauterine disease [16] while Martinez et al obtained
59% disease free survival rate in stage I-III endometrial
carcinoma at high risk for intra-abdominopelvic recur-
rence [17]. The comparison between whole abdominal
radiation therapy and Doxorubicin plus Cisplatin chemo-
therapy in a randomized phase III trial on advanced
endometrial carcinoma showed a significantly improved
progression-free and overall survival in patients treated
with chemotherapy [18].
Systemic chemotherapy has been investigated in an effort
to improve the outcome of advanced or recurring EC
[19,20]. Doxorubicin and Cisplatin have been the most
frequently used cytotoxic drugs. A few non-randomized
trials using Doxorubicin/Platinum-based regimens have
suggested that chemotherapy may be beneficial in some
patient subsets, and response rates of 42% and 38% are
reported [21,22].
Though larger-scale randomized trials are still few, post-
operative chemotherapy alone seemed to be more effec-
tive in the control of distant recurrence than in pelvic
relapses. Mundt et al. [23], in a retrospective study, evalu-
ated the efficacy of adjuvant chemotherapy on 43 high-
Table 3: Site of failure
Patient Site of relapse Stage Survival (months) Node
1 Lung-aortic node IIIA 45 DOD Not done
2 Abdomen IC 48 DOD Negative
3 Aortic nodes IC 18 DOD Negative
4 Bone III C 26 AWT Positive
5 Aortic nodes IIIA 20 DOD Not done
DOD: dead of disease
AWT: alive with tumor
Table 2: Toxicity (WHO scale)
G r a d e  1G r a d e  2G r a d e  3G r a d e  4
Leukopenia 11 52 -
Neutropenia 734-
Thrombocytopenia ----
Anemia 72--
Gastrointestinal 121-
Liver -1--
Cardiac ----
Neuropathy ----
Cystitis 12--
Alopecia ----
Emesis ----BMC Cancer 2006, 6:198 http://www.biomedcentral.com/1471-2407/6/198
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risk EC patients and reported a pelvic relapse rate of about
50%.
In a series of patients submitted to adjuvant chemother-
apy without locoregional RT, Tsunoda et al. [24] noted
recurrences in 25%, all within the pelvis. Fujimura et al.
[25] reported 15 recurrences in 25 high-risk patients
treated with adjuvant chemotherapy alone; 53% were in
the pelvis.
In the CNR study [8] EC patients were divided into low,
medium and high-risk groups. The 339 high-risk evalua-
ble patients (IC G3; IIA and IIB G3; stage III) were rand-
omized to pelvic post-operative RT or adjuvant
chemotherapy with PAC (Cisplatin, Adriamycin and
Cyclophosphamide) for five cycles. Overall survival was
not significantly different in the two groups. However,
GOG 122, a randomized trial comparing Doxorubicin/
Platinum versus radiation, found improvement in sur-
vival and progression-free survival (PFS) in patients with
stage III-IV EC treated with chemotherapy [26].
For better control of both pelvic and distant failures, com-
binations of chemotherapy and RT have been tested. The
GOG trial evaluated adjuvant Doxorubicin after surgery
and RT for high-risk EC in a randomized prospective man-
ner. After completion of RT, patients were randomized to
either the Doxorubicin treatment arm or no further treat-
ment; there was no significant difference in survival and
progression-free interval between the two arms [27].
Platinum-based chemotherapy followed by RT has also
been used. O'Brien, in a series of 26 high-risk EC patients
treated with chemotherapy (PAC) and RT, reported 57.8
% recurrences [28]; this result was similar to a non-rand-
omized group of patients treated with sequential chemo-
therapy and RT, in which there were 49% recurrences [29].
Schorge reported five-year survival of about 50% in stage
III EC patients assigned different treatments [30]. Gabriele
[31], in a series of high-risk EC patients (19 stage III, 2 IV)
treated with 3–5 cycles of PAC followed by RT, reported
an overall incidence of recurrence of 57.1%, similar to
other studies. These data show that Platinum and Doxo-
rubicin chemotherapy followed by RT is feasible and well
tolerated, but the impact of chemotherapy before adju-
vant external RT on survival has not been demonstrated in
high-risk EC.
P was introduced for the treatment of EC after its success
in ovarian and breast cancers. Three trials achieved
response rates of 36–43% when P was used as single agent
[32-34]. P has also shown activity in platinum-resistant
patients [32]. Hoskins [35] tested P and carboplatin,
alone or followed by RT, in a phase II study in advanced
and recurrent EC patients, obtaining response rates of
78% and 56% respectively in the two groups; toxicity was
manageable, reversible and mainly hematological.
We analyzed the combination of P and pelvic RT as adju-
vant treatment in high-risk EC patients. We chose P
because recent studies have indicated its efficacy as single
agent in EC [32-34]. The drug acts by enhancing microtu-
bular assembly and preventing microtubular depolymeri-
zation [36]. Another mechanism of action is of particular
interest for radiochemotherapy. P is the first member of
the taxane family, which recruits cells in the G2/M phase
of the cell cycle, in which cells are more sensitive to the
killing effects of ionizing radiation [37]. Other radiosensi-
tizing actions include inhibition of the tumoral cells'
repair capacity, lower hypoxic resistance, depletion of
sulfhydril groups, and effects on the cell membrane [38].
The weekly P regimen was planned to optimize its radio-
sensitizing action.
Several studies have defined the toxicity of concomitant P
and RT. The possibility of using P, at dosages ranging from
40 to 80 mg/m2, together with RT has already been dem-
onstrated in other tumors, without serious adverse effects
[39,40]. In our study we employed a 60 mg/m2 dosage of
P without severe side effects, except for one allergic reac-
tion.
Weekly P in association with pelvic RT is a well tolerated
regimen. In addition, we did not observe any recurrence
within the pelvis, whereas two other Italian studies
[31,41] reported high rates of pelvic relapse after sequen-
tial chemoradiation therapy. These data support the radi-
osensitizing effect of P and suggest that a delay in starting
RT might reduce its therapeutic effect. Greven [42], in a
preliminary analysis of adjuvant combined chemoradio-
therapy, also reported a low relapse rate. Concomitant
chemoradiation seems to achieve adequate pelvic control.
Comparison in recurrence rates between different kind of
postoperative treatments in endometriale cancer have
been reported in table 4.
Considering that in our series all the recurrences were out-
side the radiation field it might be useful to use a higher
dose of Taxol in consolidation cycles or to add another
active agent with a different toxic profile to improve sur-
vival in high-risk EC, and ensure better systemic control.
In conclusion, this series is obviously too small to prove
that concomitant RT and P do actually reduce relapse rates
and improve overall survival. Nevertheless, these encour-
aging results confirm the enhancing effect of this
approach in high-risk EC. Longer follow-up is now
needed to assess the outcome and randomized trials are
required.BMC Cancer 2006, 6:198 http://www.biomedcentral.com/1471-2407/6/198
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